Best Peptides for Healing: A Physician's Ranked Guide to Tissue Repair
TL;DR
BPC-157 and TB-500 have the most animal data for musculoskeletal repair, GHK-Cu for skin and collagen, KPV for gut inflammation, but human evidence for all four is preclinical or very limited and none is an approved drug. Thymosin alpha-1 is licensed in some countries for hepatitis B, not for wound healing. Proven treatments and rehab come first.
ELI5
In lab animals, different peptides help different tissues heal: BPC-157 tendons and gut, TB-500 muscle, GHK-Cu skin, KPV gut inflammation. Thymosin alpha-1 acts on the immune system. But almost none of this has been proven in people yet, so a doctor helps pick the right one — or combination — based on what's broken and what the evidence supports.
Best Peptides for Healing: A Physician's Ranked Guide to Tissue Repair

At a Glance

PeptidePrimary Healing Target (studied)Human EvidenceRegulatory StatusTypical Route
BPC-157Tendon, ligament, gut mucosaPreclinical; very limited human data (small uncontrolled series)Not approved; FDA safety-risk compounding list; WADA S0SC injection or oral
TB-500 (Tβ4 fragment)Skeletal muscle, fascia, cardiacPreclinical; no human data for the fragment (full-length Tβ4 had small phase I/II trials)Not approved; FDA safety-risk list; WADA S2.3SC injection
GHK-CuSkin, collagen matrix, nerveTopical: small human cosmetic studies; injectable: preclinical onlyInjectable on FDA safety-risk list; topical cosmetics soldTopical or SC
KPVIntestinal epithelium, skinPreclinical only (cell and mouse colitis models)Not approved; FDA safety-risk listOral or topical
Thymosin Alpha-1Immune functionLicensed in some countries for hepatitis B; large sepsis RCT was null; no wound-healing trialsNot approved by FDA or EMASC injection
CJC-1295 + IpamorelinSystemic GH releaseSmall pharmacology studies; no healing trialsNot approved; FDA safety-risk list; WADA S2.2.4SC injection

“Preclinical” means cell or animal studies. None of these peptides has a randomized human trial showing faster tissue healing.


The question I hear most often from patients — from athletes recovering from tendon injuries, from post-surgical patients, from people dealing with chronic gut ulceration — is some version of: “Is there a peptide for this?”

The honest answer is nuanced. Several peptides accelerate tissue repair in animal models through mechanisms that are well-characterised at the molecular level, but very little of that has been tested in people. But they are not interchangeable. Each operates on a different receptor system, targets a different tissue type, and carries a different risk-benefit profile. Recommending “peptides for healing” as a category is like recommending “antibiotics for infection” — directionally correct but clinically useless without specificity.

This guide ranks the most discussed healing peptides by the strength of their evidence, explains the mechanism behind each, summarises the doses used in practice, and is honest about where the human data stop.

For informational purposes only — this summarises doses used in research and practice; it is not a prescription or individual medical advice.


1. BPC-157: The Versatile Front-Runner

Body Protection Compound-157 is a synthetic pentadecapeptide derived from a protective protein found in gastric juice. It has accumulated more translational animal data than almost any other healing peptide, spanning tendon repair, ligament reconstruction, gut mucosal healing, and even peripheral nerve regeneration.

Why It Works

BPC-157 stabilises nitric oxide (NO) signalling and modulates the VEGF pathway, which drives angiogenesis — the formation of new blood vessels essential to any tissue repair cascade. It also upregulates growth hormone receptor expression in tendon fibroblasts, which may explain its consistent effect on connective tissue in animal models — and is the rationale for pairing it with a nightly GHRH peptide such as sermorelin to amplify the anabolic signalling available to repairing connective tissue. In rodent studies it also appears to work under NSAID inhibition, which disrupts COX-pathway-dependent healing. Whether any of this translates to people has not been tested in controlled trials.

Clinical Profile

For musculoskeletal injuries (Achilles tendon, ligament, muscle) BPC-157 has the largest body of animal data of any peptide here. For gut conditions including IBD, anastomoses, and mucositis, it has shown consistent results in rodents. Human data are limited to a few small uncontrolled case series, so it ranks first on volume of preclinical work, not on proof in patients.

Dosing context: 250–500 mcg once or twice daily. Oral administration is effective for gut targets; subcutaneous injection is preferred for musculoskeletal applications. Cycles of 8–12 weeks are typical in clinical practice, though no formal human RCTs have established optimal duration. Full detail: BPC-157 dosage guide.

Caution: BPC-157 is not approved by the FDA, EMA, or BfArM. The FDA lists it among bulk substances that may present significant safety risks in compounding, and WADA prohibits it (S0). Labelling a product “research use only” does not make it an approved medicine or a product tested in people.


2. TB-500 (Thymosin Beta-4): Muscle, Fascia, and Beyond

Thymosin Beta-4 — often sold as the synthetic fragment TB-500 — is a naturally occurring 43-amino-acid peptide with extraordinarily broad tissue distribution. It was first studied in cardiac healing after myocardial infarction, where it demonstrated angiogenic, anti-fibrotic, and cardiomyocyte-protective effects.

Why It Works

TB-500 promotes actin polymerisation, a fundamental step in cell migration — which is essential for fibroblasts and endothelial cells to populate an injury site. It up-regulates metalloproteinases (MMPs) that remodel scar tissue, reducing the risk of excessive fibrosis. It also modulates inflammatory signalling, shortening the inflammatory phase of healing without eliminating the immune response entirely.

Clinical Profile

Where BPC-157’s animal data centre on connective tissue and gut, thymosin beta-4’s centre on skeletal muscle, fascia, and limiting fibrotic remodelling. The two peptides are commonly stacked because their mechanisms are largely complementary rather than redundant, although no study has tested the combination in people (see the peptide stacking guide).

Dosing context: 2–2.5 mg twice weekly for 4–6 weeks (loading phase), followed by 1–1.25 mg weekly (maintenance). Always subcutaneous. The half-life is short; frequent dosing maintains tissue concentrations. Full detail: TB-500 dosage guide.

Note on cardiac and human data: The small human phase I and II trials used full-length thymosin beta-4 (intravenous safety studies, eye drops for dry eye, cardiac studies), not the TB-500 fragment sold online. The FDA notes no human exposure data for the TB-500 fragment, and WADA prohibits it (S2.3).


3. GHK-Cu: Collagen, Skin, and Neuroprotection

GHK-Cu (glycyl-L-histidyl-L-lysine copper complex) is a naturally occurring tripeptide found in human plasma, urine, and saliva. Its concentrations decline sharply with age — from roughly 200 ng/mL at age 20 to under 80 ng/mL by age 60 — a trajectory that correlates broadly with declining tissue repair capacity.

Why It Works

GHK-Cu is a potent activator of collagen, elastin, and glycosaminoglycan synthesis in fibroblasts. It resets gene expression in aged and damaged tissues toward a more youthful repair phenotype — a property documented in a widely cited analysis of human gene expression that showed GHK-Cu modulating over 4,000 genes involved in anti-inflammatory, anti-fibrotic, and tissue repair functions.

It also acts as a superoxide dismutase (SOD) mimetic via its copper complex, reducing oxidative damage in the wound microenvironment.

Clinical Profile

GHK-Cu’s best-supported area is skin: topical copper-peptide products have small human cosmetic studies on skin quality, and animal studies point to wound repair. Its peripheral nerve effects come from animal models only. Injectable GHK-Cu has no human efficacy or safety trials, and the FDA lists injectable GHK-Cu among compounding substances that may present significant safety risks.

Dosing context: Topical: 2–5% formulations applied to wound or skin twice daily. Subcutaneous: 1–2 mg daily for systemic applications. The topical route has the most documented safety data; injection protocols vary widely between practitioners. Full detail: GHK-Cu dosage guide.


4. KPV: The Gut Mucosal Specialist

KPV is a tripeptide (Lys-Pro-Val) derived from the C-terminal region of alpha-Melanocyte Stimulating Hormone (α-MSH). It is the most gut-specific of the major healing peptides, exerting potent anti-inflammatory effects at the intestinal epithelial level via direct NF-κB inhibition in enterocytes.

Why It Works

KPV’s mechanism centres on down-regulating the classical inflammatory pathway (IκBα / NF-κB) in intestinal epithelial cells and macrophages. Unlike systemic anti-inflammatory agents, KPV achieves this locally at the gut mucosa, minimising systemic immunosuppression. It also promotes epithelial barrier restoration — specifically tight junction protein expression — which is mechanistically central to leaky gut syndrome and IBD pathology.

Clinical Profile

KPV is interesting for IBD, post-infectious enteritis, and other inflammatory gut conditions, but all of its evidence so far comes from cell cultures and mouse colitis models, including orally delivered KPV nanoparticles in mice. There are no published human trials in ulcerative colitis or Crohn’s disease.

Dosing context: Oral, 500 mcg–1 mg twice daily with food. Oral delivery is effective because KPV retains bioactivity in the gut lumen. Unlike BPC-157, there is no particular advantage to injection for gut-targeted KPV use.

Stack note: KPV and BPC-157 are frequently combined in gut healing protocols. Their mechanisms are complementary — KPV suppresses inflammation while BPC-157 drives mucosal repair. The combination has not been studied in human trials, and for IBD, approved therapies with randomized evidence remain the foundation.


5. Thymosin Alpha-1: Immune-Mediated Repair

Thymosin Alpha-1 (Tα1) occupies a distinct position among healing peptides because its primary target is the immune system, not the structural tissue. It is a 28-amino-acid peptide produced naturally by the thymus gland that drives dendritic cell maturation, NK cell activation, and Treg balance.

Why It Works

In the context of healing, Thymosin Alpha-1’s relevance is greatest when immune dysfunction is impeding repair — chronic infection, immune exhaustion post-surgery, cancer-related immunosuppression, or the immune dysfunction seen in long COVID and chronic Lyme disease. It re-establishes the immune surveillance capacity that normal wound resolution requires, including clearance of senescent cells and biofilm-associated bacteria in chronic wounds.

Thymosin Alpha-1 (thymalfasin, Zadaxin) is licensed in some countries, mainly for chronic hepatitis B, which makes it the only peptide on this list with an approved indication anywhere. It is not approved by the FDA or EMA. That licence does not extend to wound healing: there are no wound-healing trials, and a large multicentre randomized trial in sepsis (TESTS, BMJ 2025) found no mortality benefit. The immune-mediated repair rationale above is mechanistic, not proven.

Dosing context: 1.6 mg subcutaneously, twice weekly for 4–6 weeks. The schedule mirrors established immunology protocols. Duration is condition-dependent. Full detail: Thymosin Alpha-1 dosage guide.

Clinical context: Tα1 is most often considered in chronic wound patients with concurrent immune compromise — post-chemotherapy, chronic Lyme, or persistent viral infections. It is not a first choice for acute musculoskeletal healing in otherwise immunocompetent patients.


6. CJC-1295 + Ipamorelin: Systemic Recovery via GH Optimisation

This peptide combination does not repair tissue directly. It raises endogenous growth hormone release, and GH and IGF-1 influence protein synthesis, collagen turnover, and sleep architecture.

The theory is that people with blunted repair capacity, such as post-surgical catabolic states, might benefit from a stronger GH axis. That has not been tested: there are no healing or recovery trials of CJC-1295 or ipamorelin, alone or combined.

Dosing context: CJC-1295 without DAC (100 mcg) + Ipamorelin (100–200 mcg) subcutaneously at bedtime, 5 nights per week. The bedtime timing aligns with the natural nocturnal GH peak and maximises synergy with deep sleep. Full detail: CJC-1295/Ipamorelin dosage guide.

Note: This combination is systemic and affects multiple systems. It is not a substitute for targeted tissue-repair peptides but functions as an adjunct in structured healing protocols. Neither compound is approved. The FDA lists both among compounding substances that may present significant safety risks, citing serious adverse events (for CJC-1295, increased heart rate and a systemic vasodilatory reaction; for ipamorelin, serious events including a death when given intravenously). WADA prohibits both (S2.2.4). For mechanism and side-effect detail, see the Ipamorelin Physician’s Guide.


How the Choice Is Usually Made

For informational purposes only — this summarises doses used in research and practice; it is not a prescription or individual medical advice.

This is the framework I use to help people weigh the options:

For acute musculoskeletal injury (tendon, ligament, muscle): BPC-157 + TB-500 combination, subcutaneous. Add CJC-1295/Ipamorelin if the patient is over 40 or systemically deconditioned. When layering additional peptides such as GHK-Cu into musculoskeletal protocols, the peptide stacking guide provides a phased loading, proliferative, and remodeling framework. Structured rehabilitation and loading remain the foundation.

For chronic gut pathology (IBD, leaky gut, post-infectious): KPV oral + BPC-157 oral, often with concurrent microbiome support, alongside a proper diagnostic work-up and approved IBD therapy where indicated.

For skin wound healing (post-surgical, ulcers, radiation injury): GHK-Cu topical as primary, +/- BPC-157 SC for deep tissue involvement, on top of standard wound care.

For immune-compromised healing: Thymosin Alpha-1 SC to restore immune scaffolding, then layer tissue-specific peptides.

For systemic recovery optimisation: CJC-1295 + Ipamorelin, particularly in athletes and post-surgical patients.

The evidence base for all of these is substantial in preclinical models but still developing in human RCTs: none of these peptides has a randomized human trial showing faster tissue healing, and the combinations have not been tested in people. They belong in the context of thorough clinical assessment, informed consent, and pharmaceutical-grade sourcing — not as over-the-counter supplements. Unapproved peptides bought online carry real risks of contamination and mislabelling (see Peptide Sourcing).



Physician-written. Written by a practicing physician at St. George Hospital. Educational content, not individual medical advice.

References

  1. Sikiric P, et al. “Brain-gut Axis and Pentadecapeptide BPC 157: Theoretical and Practical Implications.” Curr Neuropharmacol. 2016;14(8):857-865. PMID: 27138887
  2. Smart N, et al. “Thymosin β4 induces adult epicardial progenitor mobilization and neovascularization.” Nature. 2007;445(7124):177-182. PMID: 17108969
  3. Pickart L, Margolina A. “Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data.” Int J Mol Sci. 2018;19(7):1987. PMID: 29986520
  4. Dalmasso G, et al. “PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation.” Gastroenterology. 2008;134(1):166-178. PMID: 18061177
  5. Romani L, et al. “Thymosin α1 represents a potential potent single-molecule-based therapy for cystic fibrosis.” Nat Med. 2017;23(5):590-600. PMID: 28394330
  6. Chang CH, et al. “The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration.” J Appl Physiol. 2011;110(3):774-780. PMID: 21030672
  7. Wu J, et al. “The efficacy and safety of thymosin α1 for sepsis (TESTS): multicentre, double blinded, randomised, placebo controlled, phase 3 trial.” BMJ. 2025. PMID: 39814420

The Evidence Brief

Get the next deep dive in your inbox.

One evidence-graded article each week: peptides, longevity, chronic infection, immunology. Written by a practicing physician. No hype, no spam.

Email only, no medical details needed. Privacy policy.